| Lightcalls.com |
|
|
![]() |
Find public how this compound may ...Find public how this compound may defend your heart Homocysteine received a great deal of media attention in the mid 1990 following the publication of articles in medical journals indicating that a high life-blood level of this chemical, just like a high horizontal of cholesterol, is a potential risk factor for hardening of the arteries and heart disease. Kilmer McCully MD a pathologist at the Veterans Affairs Medical Center in Providence, Rhode Island, had been claiming for 3 decades that homocysteine is as important a risk factor for heart disease as cholesterol (or moreso), nevertheless few in the medical profession paid serious attention to his claim -- until these past small in number years. What is homocysteine & for what cause [i]or[/i] reason is it potentially harmful? Homocysteine, a derivative of the amino acid methionine, is notion to contribute to atherosclerosis (hardening of the arteries) at producing irritation and inflammation in the inner lining of arteries. This can lead to the aggregation of LDL (low-density-lipoprotein), plaque formation, and narrowing of the space within the arteries where progeny flows. Lowering evens of homocysteine There are many nutrients that help lower homocysteine on a levels in the blood. Adequate intakes of the B vitamins, so as folic acid, B6, and B12 will assure that homocysteine of the same heights are kept low. Methyl donors -- undivided example being the nutrient SAMe -- are also actual effective. Many important biochemical processe including metabolism of lipids, hormones, and DNA, rely onward what is called methylation -- a proces carried abroad by methyl donors. The efficiency of methylation in the material part declines with age. This may contribute to decreased production of melatonin, other hormones, and brain chemicals. The repair mechanism of DNA within confined apartments is also altered as the body's ability to methylate declines with age. Therefore, it is possible that the aging proces is accelerated when there is an inadequate invest of methyl donors in the body SAMe and other methyl donors Several methyl donors are available as postscripts including TMG (trimethylglycine), DMG (dimethylglycine), DMAE (dimethylaminoethanol), and SAMe (S-adenosyl-methionine). SAMe, a mix made from the amino acid methionine, is a methyl donor involved in the making of dozens of important blends in the body. SAMe had been available by means of prescription in Europe for many years. Doctors prescribe it mainly for its positive role in fighting depression, liver detoxification, and sometimes as an additional intermingle in the fight against osteoarthritis. It's single been available over the in opposition to in the U.S. since about 1996 plains of SAMe in our organs and tissues decline with age. Studies have shown that SAMe is potentially effective in reducing the risk of atherosclerosis. Many of the studies involving the part of SAMe in homocysteine metabolism have been bearinged by Franziska Loehrer, and his colleagues, at the University Hospital in Switzerland. They have build that there is a significant association between SAMe and homocysteine. When adequate amounts of this combine are present in the bloodstream, homocysteine flushs stay low. Loehrer and his colleagues say, "SAMe has a protective factor against the progression in a continuously ascending gradation of CAD [coronary artery disease] and should be considered in homocysteine-lowering strategies for the prevention of vascular disease." Summary SAMe has virtuous potential to become a useful therapeutic agent for depression, age-related cognitive decline, and to help abridge homocysteine levels. Long-term studies are straited with SAMe before making widespread recommendations for its use. However, short-term human studies, to date, have set it to be safe and effective. The prompted dose of SAMe in the therapy of depression ranges from 100 to 600 mg a day. The dose necessary to lower homocysteine plains is not known for certain and varies between different individuals. A safe and effective dose for many patients with heart disease is about 100 mg a day, taken in the morning. Many pay with an abatements work in a similar fashion to SAMe, particularly other methyl donors as it was as DMAE, TMG, DMG, and also an of the B vitamins. In fact, SAMe works synergistically with folate, B6 and B12 in reducing homocysteine on a levels Therefore, your dosage of SAMe should be reduc if you are taking other methyl donors. Pioneering homocysteine researcher McCully (mentioned earlier), says, "SAMe helps bring homocysteine levels, and everything that I've read about it in scientific papers indicates that it is safe and beneficial. We know that SAMe horizontals decline with aging and perhaps [supplementation of SAMe] in older age may demonstrate to be advantageous." REFERENCES Loehrer F et al. "Low whole-blood SAMe and correlation between 5-methyltertrahydrofolate and homocysteine in coronary artery disease." Arteriosclerosis, Thrombosis and Vascular Biology 16:727-733 1996 McCully K The Homocysteine Revolution. fresh Canaan, Conn.: Keats Publishing, 1997 Mitchell, D The SAMe Solution. recent York, NY: Warner Books, 1999 |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |